Parenteral Nutrition Market

Parenteral Nutrition Market Outlook from 2025 to 2035

The global parenteral nutrition market is forecast to be worth USD 6,370 million in 2025, as per Fact.MR estimates that the industry will witness a growth rate of 7.8% during the forecast period, 2025 to 2035, and will be valued at USD 13,530 million by the end of the forecast period. It is spurred mainly by the increasing number of chronic diseases and gastrointestinal complications that impair healthy nutrient absorption, thus requiring intravenous nutritional care.

An elderly population, more hospitalizations, and an escalation of preterm deliveries worldwide are further fueling demand in the parenteral nutrition market, particularly in developed healthcare setups. Parenteral nutrition (PN) is a critical part of clinical nutrition for patients who cannot take or absorb sufficient nutrients through the gastrointestinal tract.

It is utilized across neonatal intensive care units (NICUs), adult critical care, oncology, and postoperative recovery, where enteral nutrition is contraindicated or ineffective. The move towards tailored nutrition programs is driving the formation of customized PN formulations, addressing patient needs and clinical circumstances, thereby enhancing patient outcomes and reducing complications.

North America presently leads the global scene, buoyed by elevated awareness levels, robust clinical infrastructure, and common usage in intensive care environments. Europe is next in line, with desirable reimbursement environments and sophisticated clinical nutrition practices.

Nonetheless, the Asia-Pacific region has the potential to grow at the fastest rate, aided by the modernization of healthcare, increases in disposable income, and increased incidence of lifestyle diseases needing advanced nutritional therapy.

Innovation continues to grow, with greater R&D spending on lipid emulsions, micronutrient stability, and dual-chamber bag technology that improves shelf life and convenience of administration. Further, the move toward home-based PN therapy, made possible through portable infusion pumps and remote monitoring, follows the general healthcare trend toward decentralization and patient-centered care delivery.

There are several challenges, such as the threat of catheter-related bloodstream infections, electrolyte disturbances, and the requirement for strict compounding procedures. Nevertheless, strategic partnerships between healthcare professionals and pharmaceutical companies are assisting in reducing these risks while simplifying distribution and surveillance, making PN an essential, scalable intervention in contemporary medical practice.

Key Metrics

Metric	Value
Estimated Global Size in 2025	USD 6,370 million
Projected Global Size in 2035	USD 13,530 million
CAGR (2025 to 2035)	7.8%

Fact.MR Survey Results: Industry Dynamics Based on Stakeholder Perspectives

Parenteral nutrition (PN) is gaining recognition, particularly in critical and post-acute care. Based on stakeholders polled by Fact.MR, clinical safety and nutrient accuracy are the top concerns, with more than 80% of them affirming the significance of sterile compounding and traceable nutrient content, especially in long-term care. Demand for individually tailored formulations is also increasing, particularly in pediatric and organ-compromised patients, with 71% of nutritionists identifying the need for individualized admixtures.

Cost containment and variable reimbursement coverage are, however, major barriers identified by 66% of procurement managers by region. Regional variations are clear. North America shows a firm trend, with 76% of the respondents confirming its usefulness in caring for aging populations.

Europe emphasizes compounding protocol adherence and pharmacopeial quality, with Asia-Pacific being behind in specialty training, with 63% attributing gaps to secondary care center education. The uptake of technology also differs, with smart pumps and nutrient-calculation EMRs being used more in North America and Europe. At the same time, Asia-Pacific is inclined toward shelf-life-enhancing packaging.

Though there are common concerns, like irregular raw material supply and availability of pharmacists, investment priorities are split. North America is focusing on automation and mobile infusion services, Europe is focusing on sustainable packaging, and Asia-Pacific is allocating resources to academic collaborations to develop clinical nutrition capabilities. There is a general agreement across all regions on the importance of AI-driven customization tools and infrastructure improvements.

Shifts in the Market from 2020 to 2024 and Future Trends 2025 to 2035

The parenteral nutrition market experienced a steady rise from 2020 to 2024 due to increasing rates of chronic diseases, premature delivery, and gastrointestinal disorders that necessitate intravenous nutritional therapy. Improvements were happening in formulations to improve the efficiency and safety of the treatment. The growth was further driven by improvements in healthcare infrastructure, especially in the emerging world, and its contribution towards more accessible treatment with PN.

Secondly, higher home parenteral nutrition (HPN) adoption ensured greater patient-tailored therapy, wherein the patients administered nutrition to themselves under the doctor's supervision from their homes. Furthermore, the increased practice of personalized medicine contributed as the formulations for PN started becoming highly specific and based on the individualized requirements of patients.

Looking ahead to 2025 to 2035, the parenteral nutrition market will undergo tremendous change with technological advances and new treatment modalities.

Dominating trends will be the creation of more advanced and individualized PN solutions, aligning advances in biotechnology, and the growing utilization of digital health technologies to track and control PN therapy. The increasing trend of outpatient treatment and home care settings will further increase the demand for HPN. In addition, greener and eco-friendly packaging solutions for PN formulas will gain importance due to concerns about the environment and regulations.

Further, convergence of artificial intelligence (AI) and machine learning in nutrition management and planning will enable real-time, individualized adjustments in PN therapy, bettering patient outcomes and minimizing complications.

A Comparative Market Shift Analysis (2020 to 2024 vs. 2025 to 2035)

2020 to 2024	2025 to 2035
Increased incidence of chronic illnesses, premature delivery, and gastrointestinal diseases needing PN	Higher uptake of HPN, personalized nutrition, and outpatient models
New-generation PN formulations, safety and efficacy enhancements	Nutrition management by AI, biotechnology-based formulations, and digital health solutions
Increased regulatory guidelines for PN solution safety and efficacy	Higher regulation of personalized PN formulations, and eco-friendliness in packaging
The growing use of home-based PN and outpatient PN	Stricter transition towards home-based therapy and outpatient, with remote tracking and management
Growing need for the management of chronic disease, enhancing healthcare access, and personalized medicine	Advancements in technology concerning formulations, use of home care, AI enablement for dynamic real-time modifications
Emphasis on safe and efficient PN options, with consideration to sustainable packaging in some instances	Increased focus on green packaging and sustainability in PN production and distribution
Increased healthcare infrastructure, particularly in developing regions, enhances access to PN therapy.	Increasing adoption of outpatient and home care PN models, enhancing patient independence

Country-wise Analysis

Countries	CAGR (2025 to 2035)
U.S.	5.5%
UK	4.8%
France	4.6%
Germany	5.0%
Italy	4.4%
South Korea	5.1%
Japan	4.9%
China	6.0%
Australia-New Zealand	4.7%

The U.S.

The U.S. parenteral nutrition market will observe a 5.5% CAGR in the forecast period. The cases of chronic disease, the enhanced rate of hospitalization, and the increasing rate of the elderly population are robust drivers accelerating the parenteral nutrition market. An improvement in healthcare infrastructure and proximity to top-class clinical nutrition services are further fueling revenue growth. More focus on patient-focused services and personalized diet planning is also driving further growth in PN therapy. Greater concern for intensive care and post-surgery recovery malnutrition management is driving demand higher.

Emerging growth opportunities will come from future research and developments in lipid emulsions and nutrient content.

UK

The UK parenteral nutrition market is expected to grow at a 4.8% CAGR during the study period. Rising instances of chronic diseases and surgical procedures that need nutritional intervention are fueling growth. Rising demand for outpatient care is fueling trends in the parenteral nutrition market. Government policies to encourage patient nutrition and support clinical nutrition programs in hospitals are fueling revenue growth.

Innovation driven by the evolution of better formulation methods for better nutrient uptake and reducing complications is fueling innovation. Expanded facilities for critical care and oncology therapy are set to continue driving demand for PN products.

France

The French parenteral nutrition market is expected to post a 4.6% CAGR during the forecast period. Increased healthcare expenditure and greater focus on patient recovery and postoperative care are fueling the adoption of PN. The increasing prevalence of gastrointestinal disorders and conditions responsible for malabsorption of nutrients is fueling growth.

Efforts to integrate novel clinical nutrition therapies into hospital treatment regimens are fostering growth. The introduction of specialized PN products for specific patient groups is expanding the revenue size. Hospital partnerships with nutrition solution providers are also enhancing product availability and innovation.

Germany

The German parenteral nutrition market is expected to achieve 5.0% CAGR growth during the forecast period. A very advanced healthcare infrastructure and a growing emphasis on comprehensive critical care management are driving the adoption of PN. The increased number of patients requiring long-term nutritional care, especially in oncology and intensive care units, is driving demand.

The consistent presence of clinical nutrition companies and their focus on developing sophisticated, safe formulations are fueling growth. Efforts to minimize hospital stay lengths through improved nutritional support are shaping therapy practices. The development of home healthcare services also increases opportunities.

Italy

The Italian parenteral nutrition market is anticipated to rise at a 4.4% CAGR between the study years. Increasing awareness about the significance of clinical nutrition for disease management and recovery is favorably influencing growth. The rising prevalence of chronic conditions such as cancer and gastrointestinal diseases is driving PN demand.

Focusing on enhancing hospital care quality and investing in healthcare infrastructure is positively influencing revenue growth. The use of personalized nutrition regimens based on the needs of an individual patient is picking up steam. Technological advancements in the delivery systems of nutrients are poised to accelerate industry growth further.

South Korea

South Korea's parenteral nutrition market is expected to grow at a 5.1% CAGR during the study period. Rising healthcare spending and improved critical care services are major drivers of growth. Rising cancer, gastrointestinal illness, and post-surgical malnutrition cases are creating a high demand for PN therapies. The rising use of new delivery systems and customized nutritional treatments is improving patient outcomes.

Government initiatives for improved patient care quality and healthcare investment in research and innovation are spearheading growth momentum. Expansion of the private healthcare sector and a greater focus on specialized nutritional therapies are also fueling growth.

Japan

The Japanese parenteral nutrition market is expected to expand at a 4.9% CAGR during the study period. Aging demographics and the increasing burden of chronic disease are major drivers of the mounting demand for PN. Advanced healthcare and healthcare technology innovation are driving revenue growth.

Focus on enhancing patient recovery times and reducing hospital stays through effective nutritional interventions is driving the use of PN. Lipid-based and amino acid-based formulation innovations are driving improved treatment effectiveness. The growing emphasis on home health care services is offering new avenues for development.

China

The Chinese parenteral nutrition market is predicted to grow at 6.0% CAGR during the forecast period. Extremely increasing healthcare infrastructure and rising incidence of lifestyle-related diseases are fueling the demand for PN solutions. Government initiatives to make healthcare services and offer improved nutrition to patients are driving a conducive growth environment. The rising number of procedures and critical care admissions is propelling the demand for highly specialized nutritional therapy.

Healthier growth in the pharma and biotechnology sectors is fueling advancement in clinical nutrition therapy. Rising disposable income and a focus on advanced health alternatives are driving further development in the industry.

Australia-New Zealand

The Australia-New Zealand parenteral nutrition market will expand at a 4.7% CAGR during the period under study. Growing healthcare awareness and hospital infrastructure investments are favoring the parenteral nutrition market. The increasing prevalence of chronic diseases, surgeries, and malnutrition is fueling strong demand. Development in nutrient formulation and delivery systems is improving therapy efficacy and patient compliance.

Expansion in home healthcare and critical care services is also fueling the growth further. Emphasis on early nutrition intervention to enhance patient outcomes is fueling demand for specialized solutions.

Segment-wise Analysis

By Nutrient Type

In 2025, Carbohydrate-based parenteral nutrition products will emerge as the foremost segment in the Parenteral Nutrition Market, commanding 29.8% of the total share, with Parenteral Lipid Emulsion being ranked second with 24.5%.

Parenteral Nutrition Products based on carbohydrate supply energy to patients in critical condition who cannot take food by mouth or enterally. The products consist chiefly of glucose solutions necessary for maintaining the state of metabolic homeostasis and preventing catabolism in patients recovering from surgery, trauma, or critical care. The burgeoning prevalence of chronic diseases like cancer, gastrointestinal disorders, and diabetes that require special nutritional support majorly drives the demand for carbohydrate-based products.

In this segment, dominant competition is characterized by the key leaders Baxter International Inc., Fresenius Kabi, and B. Braun Melsungen AG. For instance, for patients requiring greatly customized PN carbohydrate solutions, Baxter provides a flexible assortment, while Fresenius Kabi's efforts with their glucose-based products are in the enhancement of stability and osmolarity profiles for long-term safe administration.

Parenteral Lipid Emulsion products, representing a sizeable fraction of approximately 24.5% of the parenteral nutrition market, are considered next in line. Lipid emulsions supply essential fatty acids and act as a concentrated calorie source for patients with higher energy requirements or those who cannot tolerate fluid intake. Improvements in patient care associated with evidence-based formulations of lipids, such as those with fish oils and mixed oil emulsions, have been attributed to fat emulsions that reduce inflammation and improve immune response.

The leaders in this field are Baxter, Fresenius Kabi, and Smoflipid® (by Fresenius). Next-generation lipid emulsions such as B. Braun's Lipidem® and Fresenius' Smoflipid® are based on a mix of soybean oil, MCT (medium-chain triglycerides), olive oil, and fish oil for better metabolism than the older soybean-based emulsion.

Many others are also working on extending their portfolios to ready-to-administer products, including standardized PN bags combining carbohydrates, lipids, and amino acids, designed for ease of administration in hospital and homecare settings. Pfizer Inc. and Claris Lifesciences (which has now merged into Baxter) are two major players working towards ensuring that PN therapies are safer and more efficient in clinical practice by minimizing errors associated with compounding and risks of contamination.

Competitive Outlook

The parenteral nutrition market is dominated by selected multinational pharmaceutical and healthcare firms having strategic investments in solutions for therapeutic nutrition in critical care. Baxter maintains its leadership, using an array of different parenteral formulations, integrated delivery systems, and partnerships with hospitals internationally. Following behind is Fresenius Kabi AG, which has strengths in clinical nutrition, oncology and infusion therapies, focusing on customizable and patient-specific complete PN solutions.

A strong emerging competitor, B. Braun Melsungen AG, stresses its new launches of multi-chamber bags and ready-to-administer PN systems, which bring efficiency and safety to hospital nutrition management. Pfizer, Inc. (Hospira division) retains its position by offering a diversified range of specialty injectables, including amino acid solutions, which are key to any parenteral feeding regimen. Grifols, S.A. is gearing up by deploying its expertise in biologics and plasma-derived therapies toward specialty parenteral products for immunocompromised as well as critical-care patients.

Newer entrants like Otsuka Pharmaceutical Factory and Sichuan Kelun Pharmaceutical are further loosening their competitive posture through regionally based individualized PN solutions and cost-competitive alternatives.

Market Share Analysis by Company

Company Name	Estimated Market Share (%)
Baxter	26-30%
Fresenius Kabi AG	22-26%
B. Braun Melsungen AG	15-18%
Pfizer, Inc. (Hospira)	10-13%
Grifols, S.A.	6-9%
Other Players	7-11%

Key Company Insights

Baxter leads the global parenteral nutrition market with nearly 26-30% share on account of its extensive portfolio of PN components and ready-to-use multi-chamber bag solutions. Continuous investments in sterile manufacturing and hospital-based clinical education programs reinforce Baxter's market-leading position in major regions such as North America and Europe.

Approximately 22-26% of the overall industry share is accounted for by Fresenius Kabi AG, which emphasizes a complete range of PN customizable solutions for both adult and pediatric patients and provides therapeutic nutrition solutions. The company's global distribution capabilities and expansion into emerging economies support its strengthening and enlarging footprint in the clinical nutrition space.

Thus, B. Braun Melsungen AG enjoys a revenue share of about 15-18% around the baker's dozen mark. It boasts its exclusive Nutriflex® multi-chamber technology that rationalizes hospital workflows and improves patient safety in parenteral administration practices.

Pfizer, Inc. (Hospira) holds 10-13% of the parenteral nutrition market, focusing its efforts on providing necessary parenteral amino acid, lipid and micronutrient solutions for the disastrous critical care environment, capitalizing on established networks and distribution strength in hospitals of Pfizer's creation. Grifols, S.A. seizes 6-9% share, leveraging its biological product-making expertise and hospital pharmacy partners in developing specialty PN-formulated products for vulnerable and immunosuppressed populations.

Key Players

• B. Braun Melsungen AG
• Fresenius Kabi AG
• Allergan
• Grifols, S.A.
• Pfizer, Inc. (Hospira)
• Otsuka Pharmaceutical Factory, Inc.
• Baxter
• Aculife (Nirlife)
• Sichuan Kelun Pharmaceutical Co., Ltd
• Vifor Pharma

Segmentation

• By Nutrient Type :

  • Carbohydrate-based Parenteral Nutrition Products
  • Parenteral Lipid Emulsion
  • Single Dose Amino Acid Parenteral Nutrition Solution
  • Parenteral Nutrition Trace Elements
  • Parenteral Vitamins & Minerals

• By Region :

  • North America
  • Latin America
  • Europe
  • Asia-Pacific (APAC)
  • Middle East & Africa (MEA)